Cancer stem cell-associated tumor antigen (CSC-ATA)

Cancer stem cell-associated tumor antigens (CSC-ATAs) are a specialized group of proteins expressed by cancer stem cells (CSCs), which are a subpopulation of tumor cells characterized by self-renewal, pluripotency, and high tumorigenic potential (Nassar & Blanpain, 2016, Nature). These antigens are critical targets for immunotherapy because CSCs are frequently resistant to standard treatments like chemotherapy and radiation, serving as the primary drivers of tumor recurrence and metastasis. In the context of dendritic cell (DC) vaccines, these antigens are processed and presented by Major Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) molecules on the surface of DCs to prime the adaptive immune system. This presentation triggers the activation and expansion of CSC-specific cytotoxic T lymphocytes (CTLs), which can then identify and eliminate the CSC population within the tumor microenvironment (Lu et al., 2015, J Hematol Oncol). Common CSC-ATAs include surface markers like CD133 and CD44, as well as intracellular proteins like ALDH1A1 and transcription factors such as SOX2 and OCT4 (Xu et al., 2019, Stem Cells Int). By targeting the "root" of the tumor, therapies utilizing these antigens aim to achieve durable clinical responses and prevent disease relapse.

Other names

Cancer stem cell antigenCSC antigenTumor-initiating cell antigenCSC-specific antigen

Dendritic cells (DCs) capture cancer stem cell (CSC) antigens, process them into peptides, and present them on MHC/HLA molecules to T-cells. This interaction, along with co-stimulatory signals, activates CSC-specific cytotoxic T lymphocytes (CTLs) that recognize and eliminate the CSC population in the tumor microenvironment (Lu et al., 2015, J Hematol Oncol).